June 2024 Early clinical results have shown that locally advanced (stage III) mismatch repair deficient (dMMR) rectal cancers can respond very well to immunotherapy alone, therefore allowing patients to avoid treatment with chemotherapy, radiation, or surgery. The long-term impact of immunotherapy treatment on this patient population, however, is unknown. A phase II study investigated the efficacy of the immunotherapy agent dostarlimab in patients with locally advanced dMMR or microsatellite instability high (MSI-H) rectal cancer. 47 patients with dMMR locally advanced rectal cancer were enrol ..read more

June 2024 A phase II study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting aimed to investigate whether the immunotherapy agent pembrolizumab given before surgery may improve outcomes in certain patients with stage II or III dMMR/MSI-H colorectal cancer (CRC).   Immunotherapy: a class of drugs that stimulate the body’s own immune system to more effectively target cancer cells. dMMR/MSI-H : this stands for MisMatch Repair deficient, Microsatellite Instability High. This is an important biomarker in colorectal cancer which suggests that the tumour is more l ..read more

We are pleased to announce the publication of our manuscript, “Understanding Colorectal Cancer Patient Experiences with Family Practitioners in Canada,” in Current Oncology. This study explores CRC patient experiences with family practitioners during and after diagnosis, highlighting gaps and opportunities to improve patient-centered care and outcomes across Canada. You can access the publication here. The post New! CCC Publication in Current Oncology appeared first on Colorectal Cancer Canada ..read more

We’re thrilled to announce the publication of our survey manuscript “A Survey Detailing Early Onset Colorectal Cancer Patient and Caregiver Experiences in Canada” in Current Oncology detailing the experiences of early-onset colorectal cancer patients and caregivers in Canada as part of our Never Too Young Program. You can access the publication here.     The post New CCC Publication: A Survey Detailing Early Onset Colorectal Cancer Patient and Caregiver Experiences in Canada appeared first on Colorectal Cancer Canada ..read more

We are pleased to announce the publication of our manuscript, “Understanding Colorectal Cancer Patient Experiences with Family Practitioners in Canada,” in Current Oncology. This study explores CRC patient experiences with family practitioners during and after diagnosis, highlighting gaps and opportunities to improve patient-centered care and outcomes across Canada. You can access the publication here. The post New CCC Publication: Understanding Colorectal Cancer Patient Experiences with Family Practitioners in Canada appeared first on Colorectal Cancer Canada ..read more

What is survivorship? Survivorship is a term used to describe people living with Cancer, in treatment for Cancer, who have no evidence of disease after cancer treatment, people receiving treatment for a longer period to reduce risk of Cancer returning, and people with advanced Cancer. The word “survivorship” may not fit your view of the experience you had. You may have a different word to describe your experience or current situation. Some folks will use some of the following words/phrases to articulate their unique situation: A person who has had cancer. A person who is/was impacted by cance ..read more

PERIOP-06 is a phase II study that will assess the efficacy of a medicinal product known as a Site Specific Immunomodulator (SSI) in patients who have planned to undergo surgery to remove colorectal cancer that has spread to the liver (metastases). The SSI under investigation, called QBECO, is designed to restore normal immune function in the gastrointestinal tract and related organs, including the liver, to clear and prevent cancer.   The primary objective of the PERIOP-06 trial is to assess whether giving the QBECO SSI to patients with metastatic CRC before and after their colorect ..read more

   PERIOP-06 est un essai clinique de phase II qui évaluera l’efficacité d’un médicament connu sous le nom d’immunomodulateur spécifique de site (SSI) chez des patients qui ont prévu de subir une intervention chirurgicale pour retirer un cancer colorectal qui s’est propagé au foie (métastases). Le SSI à l’étude, appelé QBECO, est conçu pour rétablir une fonction immunitaire normale dans le tractus gastro-intestinal et les organes connexes, y compris le foie, afin d’éliminer et de prévenir le cancer.       L’objectif principal de de l’étude PERIOP-06 est d’évaluer ..read more

This phase I/II clinical study will evaluate the ability of a new type of vaccine in combination with another drug, pembrolizumab (also called Keytruda), to provide a beneficial effect as a treatment for certain types of colorectal cancer (CRC).   Nous-209 is a genetic vaccine that has been developed to treat tumours that have a genetic mutation known as deficient Mismatch Repair (dMMR) or Microsatellite Instability High (MSI-H). The vaccine acts to train and arm your immune system to specifically target cancer cells in your tumour. Pembrolizumab is an approved drug and standard of c ..read more

I was diagnosed with stage 3 colon cancer in 2020. It was a fluke that I was diagnosed when I was 75 and the surgeon at Arnprior Hospital told me I did not require a colonoscopy or poop test. Fortunately when the new FIT came in they automatically sent me a test. I subsequently was diagnosed as positive. A follow up colonoscopy revealed stage 4 colon cancer. It was only 6 years since my last test. A portion of my ascending colon was removed along with 26 lymph nodes, 2 or which were cancerous. CT screening every six months identified a tumour in my lung which was removed late 2020. I was given ..read more